Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Devices

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Revenue projections:

Revenue projections for SYK
Revenue projections for SYK

SYK's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 2.112000
forwardPE 17.604187
debtToEquity 61.900000
earningsGrowth 0.142000
revenueGrowth 0.026000
grossMargins 0.649070
operatingMargins 0.155480
trailingEps 8.400000
forwardEps 16.742040

Stryker Corporation's current ratio of 2.112 indicates strong liquidity, meaning the company can comfortably meet its short-term debt obligations. This financial position reflects Stryker Corporation's ability to use its cash reserves and current assets to cover liabilities without facing any cash flow issues.
SYK's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
SYK's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in SYK's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for SYK
Price projections for SYK

The price of SYK has consistently remained close to the lower end of price projections. This trend may reflect uncertainty in the market regarding the company's ability to deliver on growth expectations.

Insider Transactions:

Insider Transactions for SYK
Insider Transactions for SYK


Stryker Corporation saw 10 transactions in which shares were sold with market price at 373.03600158691404.No sell transactions were carried out during the period under review.More buys than sells have been occurring around the current price levels of SYK, potentially signaling investor optimism. This buying trend might be interpreted as a sign of a favorable outlook for the stock's future performance.

Recommendation changes over time:

Recommendations trend for SYK
Recommendations trend for SYK


A recent buy bias from analysts toward Stryker Corporation may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that Stryker Corporation might be an appealing option for those looking to grow their wealth through stock market investments.